Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Leukemia · 2017 · PMC5419583 · PMID 27795558

Europe PMC DOI

hedged sentence

0.0300

closest p · 0.6× alpha

0.0300

boldest claim

The sentences

showed a trendp=0·03actually significant

Patients with CD33 + CD34 + CD38 low blasts showed a trend of increased prevalence of FLT3 -ITD mutation (16% vs 7%, p=0·03) and NPM1 mutation (12% vs 6%, p=0·1) ( Table S1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.